Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and pibrentasvir (Maviret) for hepatitis C.
After having reviewed the feedback, we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal.
This means that a decision will not be made in time to implement the proposal from the earliest possible listing date of 1 October 2018 that was noted in the consultation. At this stage, we do not have a firm timeframe for when a decision will be made.
If you have any questions about this update, please contact Matthew Tyson, Therapeutic Group Manager, by email at email@example.com.